(S)-2-(hydroxymethyl)-1-(quinolin-2-yl)pyrrolidine | 199117-88-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (S)-2-(hydroxymethyl)-1-(quinolin-2-yl)pyrrolidine
• 英文别名: (S)-2-Hydroxymethyl-1-(quinolin-2-yl)pyrrolidine；[(2S)-1-quinolin-2-ylpyrrolidin-2-yl]methanol
• CAS: 199117-88-9
• 化学式: C₁₄H₁₆N₂O
• 分子量: 228.294
• InChiKey: FIBOCZLMWZQYBO-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  36.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-2-(hydroxymethyl)-1-(quinolin-2-yl)pyrrolidine 在 盐酸 、 铁粉 、 sodium hydride 作用下， 以 乙醇 为溶剂， 反应 2.5h， 生成 (S)-4-<<1-(quinolin-2-yl)pyrrolidin-2-yl>methoxy>aniline
  参考文献：
  名称：

  Novel Euglycemic and Hypolipidemic Agents. 4. Pyridyl- and Quinolinyl-Containing Thiazolidinediones

  摘要：

  A series of substituted pyridyl- and quinolinyl-containing 2,4-thiazolidinediones having interesting cyclic amine as a linker have been synthesized. Both unsaturated thiazolidinediones 5 and saturated thiazolidinediones 6 and their various salts were evaluated in db/db mice for euglycemic and hypolipidemic effects and compared with BRL compound 11 and BRL-49653, respectively. Some of the potent compounds were converted to various salts in order to obtain improved activities. Among all the salts evaluated, the maleate salt of unsaturated TZD 5a was found to be a very potent euglycemic and hypolipidemic compound. Some of the more interesting compounds have also been evaluated in ob/ob mice and compared with rosiglitazone (maleate salt of BRL-49653). Oral glucose tolerance tests were performed in both db/db and ob/ob mice. Pharmacokinetic studies of 5a maleate are also reported. Receptor binding studies of PPAR gamma by 5a/5a maleate did not show any significant transactivation of PPAR alpha or PPAR gamma.

  DOI：

  10.1021/jm980622j
• 作为产物：
  描述：

  2-氯喹啉 、 L-脯氨醇 生成 (S)-2-(hydroxymethyl)-1-(quinolin-2-yl)pyrrolidine
  参考文献：
  名称：

  Heterocyclic compounds having antidiabetic, hypolipidaemic,

  摘要：

  小说式抗糖尿病化合物，它们的互变异构体，它们的衍生物，它们的立体异构体，它们的多晶形式，它们的药用可接受盐，它们的药用可接受溶剂和含有它们的药用可接受组合物; 制备抗糖尿病化合物的方法及其用途。

  公开号：

  US05919782A1

文献信息

• [EN] THIAZOLIDINEDIONE COMPOUNDS HAVING ANTIDIABETIC, HYPOLIPIDAEMIC, ANTIHYPERTENSIVE PROPERTIES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF<br/>[FR] COMPOSES DE THIAZOLIDINEDIONE PRESENTANT DES PROPRIETES ANTIDIABETIQUES, HYPOLIPIDEMIANTES, ANTIHYPERTENSIVES, LEUR PROCEDE DE PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：DR. REDDY'S RESEARCH FOUNDATION

  公开号：WO1997041120A1

  公开（公告）日：1997-11-06

  (EN) Novel thiazolidinedione antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceuticals acceptable compositions containing them; methods for preparing the antidiabetic compounds and their uses.(FR) L'invention concerne de nouveaux composés antidiabétiques de thiazolidinedione, leurs formes tautomères, leurs dérivés, leurs stéréoisomères, leurs polymorphes, leurs sels pharmaceutiquement acceptables, leurs solvates pharmaceutiquement acceptables et des compositions pharmaceutiquement acceptables les contenant, des procédés de préparation des composés antidiabétiques et leurs utilisations.

  (中) 一种新的噻唑烷酮类抗糖尿病化合物、它们的互变异构体、衍生物、立体异构体、多晶形态、药用可接受的盐、药用可接受的溶剂和含有它们的药用可接受的组合物；制备抗糖尿病化合物的方法及其用途。
• Heterocyclic compounds having antidiabetic, hypolipidaemic,
  申请人：Dr. Reddy's Research Foundation

  公开号：US05919782A1

  公开（公告）日：1999-07-06

  Novel antidiabetic compounds, their tautomeric forms, their derivatives, their steroisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceuticals acceptable compositions containing them; methods for preparing the antidiabetic compounds and their uses.

  小说式抗糖尿病化合物，它们的互变异构体，它们的衍生物，它们的立体异构体，它们的多晶形式，它们的药用可接受盐，它们的药用可接受溶剂和含有它们的药用可接受组合物; 制备抗糖尿病化合物的方法及其用途。
• THIAZOLIDINEDIONE COMPOUNDS HAVING ANTIDIABETIC, HYPOLIPIDAEMIC, ANTIHYPERTENSIVE PROPERTIES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
  申请人：DR. REDDY'S RESEARCH FOUNDATION

  公开号：EP0923580A1

  公开（公告）日：1999-06-23
• US5919782A
  申请人：——

  公开号：US5919782A

  公开（公告）日：1999-07-06
• Novel Euglycemic and Hypolipidemic Agents. 4. Pyridyl- and Quinolinyl-Containing Thiazolidinediones
  作者：B. B. Lohray、Vidya Bhushan、A. Sekar Reddy、P. Bheema Rao、N. Jaipal Reddy、P. Harikishore、N. Haritha、Reeba K. Vikramadityan、Ranjan Chakrabarti、R. Rajagopalan、K. Katneni

  DOI：10.1021/jm980622j

  日期：1999.7.1

  A series of substituted pyridyl- and quinolinyl-containing 2,4-thiazolidinediones having interesting cyclic amine as a linker have been synthesized. Both unsaturated thiazolidinediones 5 and saturated thiazolidinediones 6 and their various salts were evaluated in db/db mice for euglycemic and hypolipidemic effects and compared with BRL compound 11 and BRL-49653, respectively. Some of the potent compounds were converted to various salts in order to obtain improved activities. Among all the salts evaluated, the maleate salt of unsaturated TZD 5a was found to be a very potent euglycemic and hypolipidemic compound. Some of the more interesting compounds have also been evaluated in ob/ob mice and compared with rosiglitazone (maleate salt of BRL-49653). Oral glucose tolerance tests were performed in both db/db and ob/ob mice. Pharmacokinetic studies of 5a maleate are also reported. Receptor binding studies of PPAR gamma by 5a/5a maleate did not show any significant transactivation of PPAR alpha or PPAR gamma.